Teijin receives marketing approval for Merz’s Xeomin, Botulinum toxin


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ teijin-receives-xeomin-marketing-approval-japan
Marketing approval for Merz’s Xeomin Botulinum toxin Type A in Japan

Merz Pharmaceuticals GmbH, a leading neurotoxin company, and a subsidiary of Merz Pharma GmbH & Co. KGaA, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced today that Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity.


Xeomin is effective in treating peripheral cholinergic nerve endings by weakening the contraction of voluntary muscles, and it relieves muscle tone by inhibiting the release of a neurotransmitter called acetylcholine. The highly purified neurotoxin, the only active ingredient in Xeomin, is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables Xeomin to reduce the production of neutralizing antibodies capable of lowering efficacy.


Xeomin is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper limb spasticity, cervical dystonia, blepharospasm, or hypersalivation. Teijin Pharma signed an exclusive license and co-development agreement for Xeomin in Japan with Merz Pharma GmbH & Co. KGaA in 2017. In August 2019, Teijin Pharma applied for marketing approval based on a significant improvement in the modified Ashworth scale (MAS) score of the wrist flexion, which was observed in a phase-III clinical trial conducted by Merz in Japan.

Upper limb spasticity is a symptom of upper motor neuron syndrome, which is expressed mainly by increased muscle tone of upper limbs and the hyperexcitability of the stretch reflex as a sequela of stroke. The main symptoms are motor paralysis, hyperflexion, the appearance of pathological reflexes, and sensory disturbances that complicate or impede activities in daily living.

Conventional treatment of upper limb spasticity includes physical rehabilitation and the use of oral muscle relaxants or neuromuscular blockers such as botulinum toxin type A. Injections of botulinum toxin type A is a Grade A recommendation in the Japanese Guidelines for the Management of Stroke 2015.

"At Merz Therapeutics, we do everything to bring better outcomes to more patients. Therefore, we are very proud of our partnership with Teijin to make Xeomin® available to physicians and patients in Japan,” said Stefan Brinkmann, CEO Merz Therapeutics. “We are confident that this treatment option can help patients with upper limb spasticity in Japan to experience more good days and achieve their unique goals.”


“Teijin Pharma already provides various pharmaceuticals and medical devices that help to contribute to improving the quality of life of patients suffering from musculoskeletal diseases,” said Ichiro Watanabe, president of Teijin Pharma Limited. “We, responding to demographic change and increased health consciousness, are launching effective new drugs and providing other solutions to realize more sustainable societies. Teijin Pharma continues to contribute to improving the quality of life (QOL) of patients by providing new treatment options for diseases with high unmet needs.”

Tags : #Teijin #Xeomin #Japan #MarketingApproval #PeripheralCholinergic #MHLW

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Flight to Nowhere: The Air India Crash That Shook Ahmedabad and Raised Global Safety AlarmsJune 13, 2025
She Went for Pain Relief, Came Back With a Torn Artery: A Chiropractic Horror StoryJune 13, 2025
Biology vs Burnout: What Night Shifts Are Really Doing to Your Brain and BodyJune 13, 2025
Renowned Gynaecologist Joins Manipal Hospital Gurugram to Strengthen Women’s HealthJune 13, 2025
Aster CMI Hospital Saves Young Woman from Limb Loss in Rare Vascular SurgeryJune 13, 2025
QNET Unveils Father’s Day Gifts to Honour the Everyday Hero in Your LifeJune 13, 2025
Manipal Hospital Ghaziabad becomes first in the city to perform REZUM to treat prostate enlargementJune 13, 2025
Gen Z Doctors: Rethinking the White Coat Culture in IndiaJune 13, 2025
How Menopause Is Finally Becoming a Mainstream Medical ConversationJune 13, 2025
Thinner Bodies, Heavier Minds: When Diets Damage Mental HealthJune 13, 2025
Unite Health systems with Community-led health services to deliver on UHCJune 12, 2025
SIMS Hospital Performs India’s First Combined Open-Heart Valve Replacement and TAVR Valve-Specialised Aortic Graft SurgeryJune 12, 2025
Sodexo Partners with Medanta, Indore to Enhance Patient Dining ExperienceJune 12, 2025
University of Leeds invites applications for MSc in Air Quality Solutions with Data ScienceJune 12, 2025
IPV Leads Iom Bioworks ₹4 Cr in Seed Round to Revolutionize Healthcare Through Gut Microbiome ScienceJune 12, 2025
Rural Telehealth Fatigue: Is Screen-Based Healthcare Reaching Saturation?June 12, 2025
Medical Misinformation in the Age of Instagram: A Doctor’s DilemmaJune 12, 2025
Integrating Ayurvedic Principles into Modern Chronic Disease ManagementJune 12, 2025
Patient with multiple life-threatening conditions saved after rare, high-risk heart surgeryJune 11, 2025
Clove Oral Care Launches Its Toothpaste and Toothbrush Range, specially designed for Indian MouthsJune 11, 2025